Skip to main content
Clinical Trials/NCT06084858
NCT06084858
Completed
Not Applicable

Effect of Dialysate Bicarbonate Prescription on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients

Prim. Priv. Doz. Dr. Daniel Cejka1 site in 1 country26 target enrollmentOctober 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
End Stage Renal Disease
Sponsor
Prim. Priv. Doz. Dr. Daniel Cejka
Enrollment
26
Locations
1
Primary Endpoint
T50-Laboratory Test for measuring calcification
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal disease patients on chronic hemodiaysis.

Detailed Description

This single-arm, proof-of-principle study will be conducted at the dialysis facility of the Ordensklinikum Linz Elisabethinen Hospital. The dialysate bicarbonate prescription will be decreased from standard of care (usually 35mmol/l) in a stepwise fashion (2 mmol/l per change) to 27 mmol/l and subsequentially increased in a stepwise fashion (2 mmol/l per change) to 37 mmol/l over the course of 6 weeks.

Registry
clinicaltrials.gov
Start Date
October 1, 2023
End Date
August 1, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Sponsor
Prim. Priv. Doz. Dr. Daniel Cejka
Responsible Party
Sponsor Investigator
Principal Investigator

Prim. Priv. Doz. Dr. Daniel Cejka

Principal Investigator

Elisabethinen Hospital

Eligibility Criteria

Inclusion Criteria

  • age ≥18 years
  • chronic (≥3 months) treatment with hemodialysis or hemodiafiltration
  • stable clinical condition

Exclusion Criteria

  • inability to provide informed consent
  • dialysis treatment less than thrice weekly
  • morbid obesity (body mass index \>40 kg/m2)
  • chronic inflammation (C reactive protein \>10 mg/dL, reference: \<0.5 g/dL)
  • current immunosuppressive medication,
  • severe chronic obstructive pulmonary disease (COPD stage III or IV)
  • history of severe hypercapnia or hypoxemia
  • overt congestive heart failure
  • history of severe hypokalemia (\<3.0 mmol/l) or hyperkalemia (\>6.5 mmol/L) within 3 months prior to study inclusion.

Outcomes

Primary Outcomes

T50-Laboratory Test for measuring calcification

Time Frame: 6 Weeks

The intra-individual difference of T50-times between low (27 mmol/l) and high (37 mmol/l) dialysate bicarbonate prescription.

Secondary Outcomes

  • CPP Levels(6 Weeks)

Study Sites (1)

Loading locations...

Similar Trials